申请人:John Wyeth & Brother Limited
公开号:US04626522A1
公开(公告)日:1986-12-02
Novel benzoxazocines of formula (I) ##STR1## and their pharmaceutically acceptable acid addition salts, wherein R.sup.1 represents hydrogen, or one or more halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro, amino acylamino, mono- or di- (lower)alkyl-amino or cyano substituents, R.sup.2, R.sup.3 and R.sup.4, which may be the same or different, each represent hydrogen or lower alkyl or R.sup.3 and R.sup.4 together represent --(CH.sub.2).sub.3 --or --(CH.sub.2).sub.4 --, R.sup.5 represents hydrogen, lower alkyl, phenyl(lower)alkyl or cycloalkyl(lower)alkyl, and Ar is a phenyl radical optionally substituted by one or more halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro or amino groups exhibit activity on the central nervous system, particularly as antidepressants. The compounds can be prepared from novel alcohols of formula (II) ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and Ar are as defined above and X is fluorine, chlorine or bromine.
式(I)的新型苯并噁唑烷化合物及其药学上可接受的酸盐,其中R.sup.1代表氢,或一个或多个卤素,三氟甲基,较低的烷基,较低的烷氧基,硝基,氨基酰胺基,单或双(较低)烷基氨基或氰基取代基,R.sup.2、R.sup.3和R.sup.4可以相同也可以不同,分别代表氢或较低的烷基,或R.sup.3和R.sup.4一起代表--(CH.sub.2).sub.3--或--(CH.sub.2).sub.4--,R.sup.5代表氢,较低的烷基,苯基(较低)烷基或环烷基(较低)烷基,Ar是苯基,可选地被一个或多个卤素,三氟甲基,较低的烷基,较低的烷氧基,硝基或氨基取代,表现出中枢神经系统的活性,特别是作为抗抑郁药。这些化合物可以从式(II)的新型醇中制备而来。其中,R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5和Ar如上所定义,X是氟、氯或溴。